tetano
Editor, Senior Moderator
Am J Physiol Lung Cell Mol Physiol
. 2021 Jan 6.
doi: 10.1152/ajplung.00223.2020. Online ahead of print.
Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19
Anthony V Incognito[SUP] 1 [/SUP], Philip J Millar[SUP] 2 [/SUP], W Glen Pyle[SUP] 3 [/SUP]
Affiliations
Abstract
Acute respiratory distress syndrome and subsequent respiratory failure remains the leading cause of death (>80%) in patients severely impacted by COVID-19. The lack of clinically effective therapies for COVID-19 calls for the consideration of novel adjunct therapeutic approaches. Though novel antiviral treatments and vaccination hold promise in control and prevention of early disease, it is noteworthy that in severe cases of COVID-19, addressing "run-away" inflammatory cascades are likely more relevant for improvement of clinical outcomes. Viral loads may decrease in severe, end-stage coronavirus cases, but a systemically damaging cytokine storm persists and mediates multiple organ injury. Remote ischemic conditioning (RIC) of the limbs has shown potential in recent years to protect the lungs and other organs against pathological conditions similar to that observed in COVID-19. We review the efficacy of RIC in protecting the lungs against acute injury and current points of consideration. The beneficial effects of RIC on lung injury along with other related cardiovascular complications are discussed, as are the limitations presented by sex and ageing. This adjunct therapy is highly feasible, non-invasive, and proven to be safe in clinical conditions. If proven effective in clinical trials for acute respiratory distress syndrome and COVID-19, application in the clinical setting could be immediately implemented to improve outcomes.
Keywords: COVID-19; acute respiratory distress syndrome; remote ischemic conditioning.
. 2021 Jan 6.
doi: 10.1152/ajplung.00223.2020. Online ahead of print.
Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19
Anthony V Incognito[SUP] 1 [/SUP], Philip J Millar[SUP] 2 [/SUP], W Glen Pyle[SUP] 3 [/SUP]
Affiliations
- PMID: 33404365
- DOI: 10.1152/ajplung.00223.2020
Abstract
Acute respiratory distress syndrome and subsequent respiratory failure remains the leading cause of death (>80%) in patients severely impacted by COVID-19. The lack of clinically effective therapies for COVID-19 calls for the consideration of novel adjunct therapeutic approaches. Though novel antiviral treatments and vaccination hold promise in control and prevention of early disease, it is noteworthy that in severe cases of COVID-19, addressing "run-away" inflammatory cascades are likely more relevant for improvement of clinical outcomes. Viral loads may decrease in severe, end-stage coronavirus cases, but a systemically damaging cytokine storm persists and mediates multiple organ injury. Remote ischemic conditioning (RIC) of the limbs has shown potential in recent years to protect the lungs and other organs against pathological conditions similar to that observed in COVID-19. We review the efficacy of RIC in protecting the lungs against acute injury and current points of consideration. The beneficial effects of RIC on lung injury along with other related cardiovascular complications are discussed, as are the limitations presented by sex and ageing. This adjunct therapy is highly feasible, non-invasive, and proven to be safe in clinical conditions. If proven effective in clinical trials for acute respiratory distress syndrome and COVID-19, application in the clinical setting could be immediately implemented to improve outcomes.
Keywords: COVID-19; acute respiratory distress syndrome; remote ischemic conditioning.